Rhythm Pharmaceuticals (RYTM) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 351.9% versus a loss of 10.6%. Over five years, RYTM leads with a +692.6% price change compared with -60.9% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.37 billion vs $6.17 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RYTM | SYRE |
|---|---|---|
| Share price | $89.64 | $79.90 |
| Market cap | $6.17B | $7.37B |
| 1-day change | +1.35% | -1.18% |
| YTD return | -16.26% | +143.89% |
| 1-year return | -10.57% | +351.92% |
| 5-year return | +692.57% | -60.93% |
| EPS (TTM) | $-3.16 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $189.76M | $0 |
| Revenue growth (YoY) | +45.83% | — |
| Net income (latest FY) | $-196.54M | $-155.20M |
| Gross margin | 89.73% | — |
| Operating margin | -101.19% | — |
| Net margin | -103.57% | — |
| 52-week high | $122.20 | $110.18 |
| 52-week low | $74.50 | $17.65 |
| Distance from 52-week high | -26.64% | -27.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +54.61% | +50.45% |
| Average volume | 649.06K | 1.20M |
| Shares outstanding | 68.85M | 92.29M |
| Employees | 414 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed RYTM by 362.5 percentage points over the past year.
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
RYTM vs SYRE FAQ
Which is bigger, Rhythm Pharmaceuticals or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.37B compared with $6.17B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, RYTM or SYRE?
SYRE returned +351.92% over the past 12 months, compared with -10.57% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Rhythm Pharmaceuticals and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.